NDA 010669 · Waylis Therap
Leukeran
Chlorambucil · Oral · Alkylating Drug
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Oct 28, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1957
Mar 18, 1957
Approved uses
1
Original approval plus efficacy supplements
Registered trials
61
34 Phase 3, 1 recruiting
FAERS reports
3,931
3,662 serious, 929 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).
What it is approved for
From the label in effect Jan 8, 2025.
INDICATIONS AND USAGE LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.
Mechanism: Mechanism of Action Chlorambucil, an aromatic nitrogen mustard derivative, is an alkylating agent. Chlorambucil interferes with DNA replication and induces cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bax, an apoptosis promoter.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 18, 1957 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- LEUKERAN · CHLORAMBUCIL 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorambucil" as an intervention, any sponsor and status, largest first.
- A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic LeukemiaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01905943 · 979 participants · Start Nov 4, 2013 · Primary completion Dec 29, 2016
Drug: Bendamustine; Chlorambucil and 3 more · For: Chronic Lymphocytic Leukemia
Sites: Santa Fe, Argentina; Brussels, Belgium; Hasselt, Belgium · 174 sites in all
- Combination Chemotherapy in Treating Patients With Advanced Hodgkin's DiseasePivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00003421 · 800 participants (planned) · Start Jun 1998
Drug: bleomycin sulfate; ABVD regimen and 8 more · For: Lymphoma
Sites: Leeds, United Kingdom; Sheffield, United Kingdom
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01010061 · 787 participants · Start Dec 21, 2009 · Primary completion Jul 1, 2012
Drug: obinutuzumab; rituximab and 1 more · For: Lymphocytic Leukemia, Chronic
Sites: San Diego, California; Chicago, Illinois; Baltimore, Maryland · 261 sites in all
- CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01998880 · 787 participants · Start Dec 22, 2009 · Primary completion Aug 1, 2012
Drug: obinutuzumab; rituximab and 1 more · For: Lymphocytic Leukemia, Chronic
Sites: San Diego, California; Chicago, Illinois; Baltimore, Maryland · 261 sites in all
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02053610 · 787 participants · Start Dec 31, 2009 · Primary completion Aug 31, 2013
Drug: obinutuzumab; rituximab and 1 more · For: Lymphocytic Leukemia, Chronic
Sites: San Diego, California; Chicago, Illinois; Baltimore, Maryland · 261 sites in all
- A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive TreatmentPivotal-lookingStatus unknown
University of LiverpoolAcademic, hospital or other
NCT01678430 · 670 participants (planned) · Start Dec 2011 · Primary completion Dec 2017
Drug: Ofatumumab; Chlorambucil and 1 more · For: Chronic Lymphocytic Leukaemia
Sites: Chester, United Kingdom; Plymouth, United Kingdom; Torquay, United Kingdom · 28 sites in all
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
TG Therapeutics, Inc.Industry
NCT02612311 · 603 participants · Start Nov 19, 2015 · Primary completion Feb 22, 2023
Drug: Obinutuzumab; Ublituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Huntsville, Alabama; Mobile, Alabama; Chandler, Arizona · 154 sites in all
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLPivotal-lookingCompleted
Acerta Pharma BVAstraZeneca (AZN)
NCT02475681 · 535 participants · Start Jun 26, 2015 · Primary completion Feb 8, 2019
Drug: Acalabrutinib; Obinutuzumab and 1 more · For: Chronic Lymphocytic Leukemia
Sites: Goodyear, Arizona; Phoenix, Arizona; Anaheim, California · 155 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia279
- pneumonia272
- off label use269
- pyrexia243
- drug ineffective204
- thrombocytopenia199
- anaemia164
- febrile neutropenia162
- disease progression156
- acute myeloid leukaemia131
- infection126
- dyspnoea125
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 47 |
| 2005 | 53 |
| 2006 | 35 |
| 2007 | 38 |
| 2008 | 71 |
| 2009 | 72 |
| 2010 | 127 |
| 2011 | 190 |
| 2012 | 215 |
| 2013 | 160 |
| 2014 | 212 |
| 2015 | 207 |
| 2016 | 294 |
| 2017 | 281 |
| 2018 | 457 |
| 2019 | 352 |
| 2020 | 267 |
| 2021 | 224 |
| 2022 | 178 |
| 2023 | 152 |
| 2024 | 134 |
| 2025 | 103 |
| 2026 | 62 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Leukeran (Chlorambucil)
2024 spending
$16.9M
Beneficiaries
183
876 claims
Per beneficiary
$92,560
$536.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $6,822,419 |
| 2024 | $16,938,541 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, et al. · Blood 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Sharman JP, Egyed M, Jurczak W, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP, Owen C, Moreno C, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU, Munir T, Moreno C, et al. · Lancet Oncol 2023 · Randomized Controlled Trial, Multicenter Study
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA, Tedeschi A, Barr PM, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.